MicroRNAs in Renal Cell Carcinoma Diagnostic Implications of Serum miR-1233 Levels 英文参考文献.docVIP

MicroRNAsinRenalCellCarcinoma:Diagnostic ImplicationsofSerummiR-1233Levels LenaM.Wulfken1,RudolfMoritz2,CarstenOhlmann3,StefanHoldenrieder4,VolkerJung3 ,Frank Becker3,5,EdwinHerrmann2,GiselaWalgenbach-Bru¨nagel5,AlexandervonRuecker6,StefanC.Mu¨ller1, Jo¨rgEllinger1* 1 Klinik und Poliklinik fu¨r Urologie und Kinderurologie, Universita¨tsklinikum Bonn, Bonn, Germany, 2 Klinik und Poliklinik fu¨ r Urologie, Universita¨tsklinikum Mu¨ nster, Mu¨nster, Germany, 3 Klinik und Poliklinik fu¨ r Urologie, Universita¨tsklinikum des Saarlandes, Homburg/Saar, Germany, 4 Institut fu¨r Klinische Chemie und Klinische Pharmakologie, Universita¨tsklinikum Bonn, Bonn, Germany, 5 Urologische Gemeinschaftspraxis und Ambulatorium Derouet/Poenicke/Becker, Neunkirchen, Germany, 6 Institut fu¨ r Pathologie, Universita¨tsklinikum Bonn, Bonn, Germany Abstract Background: MicroRNA expression is altered in cancer cells, and microRNAs could serve as diagnostic/prognostic biomarker for cancer patients. Our study was designed to analyze circulating serum microRNAs in patients with renal cell carcinoma (RCC). Methodology/PrincipalFindings: We first explored microRNA expression profiles in tissue and serum using TaqMan Low Density Arrays in each six malignant and benign samples: Although 109 microRNAs were circulating at higher levels in cancer patients’ serum, we identified only 36 microRNAs with up-regulation in RCC tissue and serum of RCC patients. Seven candidate microRNAs were selected for verification based on the finding of up-regulation in serum and tissue of RCC patients: miR-7-1*, miR-93, miR-106b*, miR-210, miR-320b, miR-1233 and miR-1290 levels in serum of healthy controls (n = 30) and RCC (n = 33) patients were determined using quantitative real-time PCR (TaqMan MicroRNA Assays). miR-1233 was increased in RCC patients, and thus validated in a multicentre coho